

Unituxin Patent, Sales & Clinical Trials Outlook 2028

<https://marketpublishers.com/r/U6E6586B762BEN.html>

Date: October 2021

Pages: 57

Price: US\$ 800.00 (Single User License)

ID: U6E6586B762BEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Unituxin Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights:

Unituxin Patent Insight

Unituxin Dosage & Price

Unituxin Sales Forecast 2028: > USD 500 Million

Unituxin Role in Cancer Therapy

Unituxin Structure & Pharmacokinetics Properties

Unituxin Ongoing Clinical Trials: > 10 Clinical Studies

Unituxin Reimbursement Scenario

Neuroblastoma is an embryonic cancer of the post-ganglionic sympathetic nervous system. The treatment with conventional cancer therapies are associated with poor survival outcomes, thus posing high medical needs for the development of targeted therapies. Genomic analysis of neuroblastoma has revealed high expression of GD2 on cancer cells. Owing to its restricted expression in normal cells, targeting GD2 has proven to be effective for the treatment of cancer. Researchers have developed GD2 targeting antibodies which work by targeting GD2 receptor on cancer cells.

Unituxin (dinutuximab) is first approved disialoganglioside, GD2-binding chimeric

monoclonal antibody. The drug was developed by United Therapeutics Corporation and is indicated for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Owing to its targeted mechanism of action, the drug has shown high adoption rates in the market. The drug was also approved in Europe, but it was later discontinued due to short- and intermediate- term inability to supply Unituxin in sufficient quantities for meeting current global demands.

Recently, scientists have also developed dinutuximab beta which is another version of dinutuximab. The dinutuximab was developed is manufactured using mouse cells, whereas dinutuximab beta is manufactured using hamster cells. Following withdrawal of Unituxin, European Medicines Agency has rapidly approved Qarbiza (dinutuximab beta) for the treatment of neuroblastoma. More recently, China National Medical Products Administration (NMPA) has granted Qarbiza conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

Currently the drug Unituxin is mainly indicated for the management of neuroblastoma. However, ongoing clinical trials are also evaluating the role of these drugs in the treatment of other cancers also including osteosarcoma and small cell lung cancer. In addition, several ongoing clinical trials are also evaluating the role of drug in combination with other cancer targeting regimens. The coming years will witness rapid approval of drug as monotherapy or combinational therapy in wide range of cancers, which will further propel the growth of market during the forecast period.

As per report findings, the global Unituxin market is currently present at nascent stage and will grow slow growth rates during the forecast period. Several factors including increase in prevalence of cancer, no competition from generic drugs, rising awareness about the availability of drug and robust sales of Unituxin in global market will boost the growth of market. In addition to this, the high adoption rates of novel therapy as well as rising initiative by government to initiate research and development activities will also drive the future of the market. In addition, it will also face competition from novel emerging GD2 targeting drugs which are expected to enter the market during forecast period.

Presently, US holds the top position in the market and is expected to maintain its position during the forecast period due to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing

funding by the government to promote research and development. In addition to this, the rise in prevalence of cancer and the increase awareness for the acceptance of novel therapies is also going to drive the future of the market. Moreover, the global market will be driven the rising approval of these drugs in other regions such as Europe, China and Asia and their increasing applications in other cancers. Our report provides detailed analysis on Unituxin including its price, sales, dosage, and clinical trial insights. On the basis of this, the future sales of the drug have been forecasted and market opportunity of drug in neuroblastoma as well as small cell lung cancer has been established.

Contents

1. UNITUXIN (DINUTUXIMAB) FIRST APPROVED ANTI-GD2 TARGETING IMMUNOTHERAPY

1.1 Overview

1.2 Approval & Patent Insight

2. UNITUXIN COMMERCIAL INFORMATION

2.1 Dosage & Price Analysis

2.2 Sales Analysis

3. DINUTUXIMAB - STRUCTURE, DESCRIPTION & PHARMACOKINETICS

4. UNITUXIN MECHANISM OF ACTION

5. ROLE OF UNITUXIN IN NEUROBLASTOMA

6. ROLE OF UNITUXIN IN SCLC

7. UNITUXIN - SUPPLEMENTARY INFORMATION

7.1 Adverse Drug Reactions

7.2 Application in Specific Population

7.3 Nonclinical Toxicology

8. UNITUXIN MARKET ANALYSIS

8.1 Current Market Scenario

8.2 Future Market Opportunity

9. UNITUXIN SALES FORECAST

10. UNITUXIN REIMBURSEMENT POLICY

11. UNITUXIN CLINICAL TRIAL INSIGHT

11.1 By Phase

11.2 By Development Status

11.3 By Region

12. COMPANIES DEVELOPING GD2 TARGETING IMMUNOTHERAPIES

12.1 Bellicum Therapeutics

12.2 MabVax Therapeutics

12.3 Shanghai Yake Biotechnology

12.4 Sinobioway Cell Therapy

12.5 Sorentto Therapeutics

12.6 United Therapeutic Corporation

12.7 Y-mAbs Therapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Unituxin – Approval Year by Region

Figure 1-2: Unituxin – Orphan Designation Year by Region

Figure 1-3: US – Unituxin FDA Approval & Patent Exclusivity Year

Figure 1-4: US – Unituxin Orphan Approval & Exclusivity Expiration Year

Figure 1-5: Europe – EMA Approval & Market Withdrawal Year

Figure 2-1: Unituxin – Cost of Supply of 5ml & Per Unit Cost of Intravenous Solution (US\$), October'2021

Figure 2-2: Unituxin – Duration of Treatment (Days)

Figure 2-3: Unituxin – Cost of Single Cycle & Full Treatment Cost (US\$)

Figure 2-4: Global – Unituxin Annual Sales (US\$ Million), 2017-2020

Figure 2-5: Global – Unituxin Quarterly Sales (US\$ Million), 2020

Figure 2-6: Global – Unituxin Quarterly Sales (US\$ Million), 2020

Figure 2-7: Global – Unituxin Quarterly Sales (US\$ Million), Q1 & Q2, 2021

Figure 2-8: Global – Unituxin Half Yearly Sales (US\$ Million), H1, 2020 & 2021

Figure 4-1: Role of GD2 in Cancer

Figure 4-2: General Pathways of GD2 Targeting Immunotherapies

Figure 4-3: Interaction of GD2 & Unituxin

Figure 4-4: Unituxin – Mechanism Of Action

Figure 5-1: Global – Newly Diagnosed Cases of Neuroblastoma, 2020 & 2028

Figure 5-2: Impact of GD2 Targeting Immunotherapies on Lung Cancer

Figure 6-1: Global – Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020

Figure 6-2: Global – Lung Cancer Incidence by Type (%), 2020

Figure 6-3: Impact of GD2 Targeting Therapy on SCLC

Figure 7-1: Unituxin Associated Adverse Events

Figure 8-1: Global – Newly Diagnosed Cases of Neuroblastoma, 2020-2028

Figure 8-2: Global – Unituxin Market Opportunity by 2% of Neuroblastoma Population (US\$ Million), 2021 - 2028

Figure 8-3: Global – Unituxin Market Opportunity by 4% of Neuroblastoma Population (US\$ Million), 2021 - 2028

Figure 8-4: Global – Unituxin Market Opportunity by 6% of Neuroblastoma Population (US\$ Million), 2021 - 2028

Figure 8-5: Global – Unituxin Market Opportunity by 8% of Neuroblastoma Population (US\$ Million), 2021 - 2028

Figure 8-6: Global – Unituxin Market Opportunity by 10% of Neuroblastoma Population

(US\$ Million), 2021 - 2028

Figure 8-7: Global – Estimated SCLC Population for Unituxin, 2021-2028

Figure 9-1: Global – Unituxin Sales Forecast (US\$ Million), 2020-2028

Figure 10-1: Global – Unituxin Reimbursed Sales (%)

Figure 10-2: Global – Unituxin Incremental Budget Impact (US\$/3 Years)

Figure 11-1: Global – Number of Unituxin Related Clinical Trials by Phase,
October'2021

Figure 11-2: Global – TROP2 Related Clinical Trials by Phase (%), October'2021

Figure 11-3: Global – Number of Unituxin Related Clinical Trials by Development
Status, October'2021

Figure 11-4: Global – Number of Unituxin Related Clinical Trials by Development Status
(%), October'2021

Figure 11-5: Global – Number of Unituxin Related Clinical Trials by Region,
October'2021

I would like to order

Product name: Unituxin Patent, Sales & Clinical Trials Outlook 2028

Product link: <https://marketpublishers.com/r/U6E6586B762BEN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U6E6586B762BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970